Lesson
Build the Diagnostic Frame Before Treating
Vulvovaginal symptoms overlap. History defines probability and urgency, but pH, examination, microscopy, molecular testing, culture, and an explicit noninfectious differential determine what should be treated.
- Syndrome
- Vaginal pH
- Wet mount
- NAAT
- Culture
- Red flags
Symptoms, exposures, pregnancy, medicines, recurrence
Use objective findings to narrow the field
Match method sensitivity to the organism
Protect cervicitis, upper tract, and noninfectious pathways
Start with the whole symptom pattern
Ask about discharge, odor, pruritus, burning, vulvar pain, external dysuria, dyspareunia, bleeding, pelvic pain, fever, lesions, pregnancy, sexual exposure, hygiene products, douching, antibiotics, diabetes, immune status, and prior self-treatment. No single symptom identifies the cause.
Structure the self-care interview
Move from the current symptoms to onset, duration, location, aggravating and relieving factors, prior episodes, attempted treatments, medicines, allergies, pregnancy possibility, sexual exposure, and medical conditions. A familiar label from a prior episode does not replace a fresh assessment.
Use pH as a routing clue
A pH above 4.5 is common with bacterial vaginosis or trichomoniasis. Candidiasis usually preserves a pH below 4.5. Blood, semen, douching, and collection conditions can alter the result, so pH never stands alone.
Read bedside microscopy cautiously
Saline wet mount can show clue cells, motile trichomonads, and inflammatory cells. Potassium hydroxide preparation can reveal budding yeast, hyphae, or pseudohyphae. Limited sensitivity means that a negative wet mount does not end the evaluation when suspicion remains.
Escalate testing by phenotype
Use validated NAAT for trichomoniasis and selected vaginitis panels when available. Obtain fungal culture or validated species-level testing for complicated, recurrent, severe, or persistent candidiasis. Interpret a detected organism in the context of symptoms because colonization can occur.
Protect the red-flag pathway
Fever, toxic appearance, pelvic or abdominal pain, cervical motion tenderness, pregnancy complications, genital ulcers, marked bleeding, retained foreign body, rapidly progressive swelling, or persistent unexplained symptoms require focused evaluation beyond routine vaginitis care.
Quick check
Checking for saved practice…
Lesson
Recognize Bacterial Vaginosis as an Ecosystem Disorder
Bacterial vaginosis reflects loss of protective Lactobacillus activity, expansion of diverse anaerobes, higher pH, and often a polymicrobial biofilm. Diagnosis requires a validated pattern, not one organism or one symptom.
- Dysbiosis
- Lactobacillus
- Anaerobes
- Biofilm
- Amsel criteria
- Nugent score
Lactate and low pH support colonization resistance
Diverse organisms replace the protective community
Adherent communities can survive initial disturbance
Combine independent findings rather than trusting odor alone
Describe the microbial shift
Protective lactate-producing communities are reduced while anaerobic organisms and bacterial diversity increase. Gardnerella can participate, but BV is not adequately described as a single-organism infection.
Use Amsel criteria correctly
A clinical Amsel diagnosis requires at least three of four findings: homogeneous thin discharge, vaginal pH above 4.5, clue cells, and an amine odor after potassium hydroxide is added.
Use laboratory methods in context
Nugent scoring interprets bacterial morphotypes on Gram stain. Validated molecular tests identify characteristic organism patterns. A positive molecular result in an asymptomatic patient still requires clinical interpretation rather than automatic treatment.
Separate association from blame
Sexual activity and partner microbiota can influence occurrence and recurrence, but BV is not proof of infidelity and can occur without recent vaginal intercourse. Douching can increase relapse risk and is not a treatment.
Recognize clinical consequences
Symptomatic disease warrants treatment. BV is associated with STI acquisition, pregnancy complications, recurrence, and postoperative risk, but screening and treatment decisions for asymptomatic patients depend on the clinical setting.
Quick check
Checking for saved practice…
Lesson
Select and Deliver Bacterial Vaginosis Therapy
Recommended oral and intravaginal regimens can all be appropriate. Route, vehicle, pregnancy, lactation, interactions, adherence, cost, recurrence, and exact product instructions determine which regimen is usable.
- Metronidazole
- Clindamycin
- Tinidazole
- Secnidazole
- Vaginal vehicle
- Administration
Seven days with systemic interaction review
Lower systemic exposure with exact applicator technique
Vehicle determines barrier-method counseling
Preparation and lactation instructions are part of the dose
Use a recommended CDC option
Recommended regimens include metronidazole 500 mg orally twice daily for seven days, metronidazole gel 0.75 percent, 5 g intravaginally daily for five days, or clindamycin cream 2 percent, 5 g intravaginally at bedtime for seven days.
Keep alternative regimens visible
Alternatives include oral clindamycin 300 mg twice daily for seven days; clindamycin 100 mg vaginal ovules nightly for three days; oral tinidazole 2 g daily for two days or 1 g daily for five days; or secnidazole 2 g orally once. Convenience, prior response, tolerability, cost, pregnancy, lactation, and access determine whether an alternative fits.
Complete associated testing
Patients with BV should also receive HIV and other STI testing. Do not use a BV diagnosis to exclude a concurrent infection.
Counsel nitroimidazoles precisely
Metronidazole, tinidazole, and secnidazole share a mechanism but not one regimen. Review warfarin and other interactions, GI and neurologic effects, prior hypersensitivity, candidiasis risk, and the current product-specific pregnancy and lactation information.
Treat the dosage form as pharmacology
Intravaginal clindamycin creams, ovules, and gels have different vehicles and barrier-method instructions. Read the exact product label rather than copying a latex warning from another formulation.
Separate clindamycin vehicle warnings
Conventional 2% cream can weaken latex barriers for five days after use; ovules carry a 72-hour warning. Xaciato gel instead warns against polyurethane condoms during treatment and for seven days afterward, with latex or polyisoprene alternatives. Its label also directs avoiding vaginal intercourse and other vaginal products for three days after treatment. New significant diarrhea warrants evaluation for C. difficile even after vaginal clindamycin.
Reconcile alcohol advice with labeling
CDC BV guidance finds the evidence for a metronidazole disulfiram-like interaction unconvincing and does not require alcohol abstinence. Current oral metronidazole labeling nevertheless directs avoidance of alcohol and propylene glycol during treatment and for at least three days afterward. Explain this discrepancy, follow the dispensed product counseling plan, and do not present the proposed interaction mechanism as established fact. Metronidazole is also contraindicated with disulfiram taken within the prior two weeks and in Cockayne syndrome.
Teach secnidazole preparation
For the labeled single 2 g packet, sprinkle all granules onto applesauce, yogurt, or pudding, consume the mixture within 30 minutes without chewing or crunching, and do not dissolve the granules in liquid. Current labeling advises a 96-hour breastfeeding interruption and avoidance of alcohol or preparations containing ethanol or propylene glycol during treatment and for two days afterward.
Quick check
Checking for saved practice…
Lesson
Manage Recurrent Bacterial Vaginosis with Updated Evidence
Recurrent BV is common and frustrating. Confirm the current syndrome, identify modifiable exposures and competing diagnoses, then choose retreatment, suppression, or selected partner therapy with a defined reassessment plan.
- Recurrence
- Retreatment
- Suppression
- Partner therapy
- 2025 ACOG update
- Shared decision making
Rule out candidiasis, trichomoniasis, and noninfectious disease
Define induction, duration, and stop point
Apply the 2025 ACOG pathway to selected patients
Track symptom-free interval and treatment exposure
Confirm before escalating
Review whether the prior regimen was completed, whether symptoms resolved, the symptom-free interval, sexual exposure, douching, candidiasis, trichomoniasis, cervicitis, and noninfectious causes. Reconfirm BV when the phenotype is uncertain.
Use retreatment deliberately
A first recurrence can be treated with a different recommended regimen or the same regimen when appropriate. For multiple recurrences, CDC describes 0.75% vaginal metronidazole gel twice weekly for more than three months. Benefit may fade after stopping. Confirm the diagnosis and use clinician-directed suppression with candidiasis monitoring and a reassessment point.
Understand the older baseline
The 2021 CDC guideline does not recommend routine partner treatment based on older trials. That remains important context for first episodes, asymptomatic disease, and populations not represented by newer evidence.
Apply the 2025 ACOG update
After a 2025 randomized trial, ACOG recommends considering concurrent oral and topical antimicrobial treatment for male partners of adults with recurrent symptomatic BV. ACOG also supports shared decision making for same-sex partners and selected first episodes while recognizing evidence gaps.
Make partner prescribing concrete
The 2026 NYSDOH pathway uses oral metronidazole 500 mg twice daily for seven days plus clindamycin 2% cream to penile skin twice daily for seven days. This is off-label cream use; neither 2% vaginal gel nor 1% skin preparations are substitutes. Give explicit skin-application instructions and coordinate treatment completion and temporary abstinence for both partners. Clindamycin may impair condom integrity. This pathway requires clinician assessment; do not assume STI expedited-partner rules cover BV in every jurisdiction.
Respect population boundaries
Do not convert one trial in monogamous heterosexual couples into universal therapy for every partner, asymptomatic patient, nonmonogamous relationship, or pregnancy. Document the evidence, patient preference, antimicrobial risks, partner access, and follow-up.
Quick check
Checking for saved practice…
Lesson
Treat Trichomoniasis as a Patient and Partner System
Trichomoniasis requires accurate testing, population-specific oral nitroimidazole therapy, concurrent treatment of partners, abstinence through treatment and symptom resolution, and retesting because reinfection is common.
- Trichomonas vaginalis
- NAAT
- Metronidazole
- Partner treatment
- Retesting
- Resistance
Wet mount alone can miss infection
Use the population-specific regimen
Prevent predictable reinfection
Assess exposure before attributing recurrence to resistance
Diagnose with a sensitive test
NAAT is preferred when available. Wet mount can show motile trichomonads but has limited sensitivity, and delayed slide reading reduces sensitivity further. Also test for HIV, syphilis, gonorrhea and chlamydia.
Use population-specific therapy
CDC recommends metronidazole 500 mg orally twice daily for seven days for women and 2 g orally once for men. Tinidazole 2 g orally once is an alternative for women and men. Intravaginal metronidazole is not adequate therapy for trichomoniasis.
Distinguish an approved additional option
Secnidazole also has an FDA-labeled trichomoniasis regimen: 2 g orally once for patients aged 12 or older, with simultaneous partner treatment. This approval does not erase the CDC preference for seven-day metronidazole in women. Secnidazole is contraindicated in Cockayne syndrome and nitroimidazole hypersensitivity; avoid chronic use.
Add HIV-specific screening
For women with HIV, screen at entry to care and at least annually; during pregnancy screen at the first prenatal visit. Confirmed infection uses metronidazole 500 mg twice daily for seven days, with retesting at three months.
Treat current partners
Current sexual partners should receive presumptive treatment. Patients and partners should avoid sex until therapy is complete and symptoms have resolved. Expedited partner therapy may be used where legally permissible and clinically appropriate.
Plan retesting
Women should be retested approximately three months after treatment because reinfection is common. If three-month testing is not possible, retest when the patient next seeks care within 12 months.
Separate intolerance from allergy
An IgE-mediated nitroimidazole allergy requires specialist-guided metronidazole desensitization planning. Simply changing to another nitroimidazole is not a safe substitute for allergy assessment.
Investigate persistence
First exclude nonadherence and re-exposure. For persistent or recurrent symptoms, culture is preferred. If using NAAT, wait at least three weeks after treatment completion to avoid detecting residual nucleic acid. When resistance is plausible, use CDC consultation and susceptibility support rather than improvising repeated single doses.
Quick check
Checking for saved practice…
Lesson
Separate Candida Colonization from Candidiasis
Candida detection is not synonymous with disease. Compatible symptoms and signs, pH, microscopy, culture, species, host factors, severity, recurrence, and response divide uncomplicated VVC from complicated disease.
- Candida
- Colonization
- KOH microscopy
- Culture
- Complicated VVC
- Species
Pruritus, soreness, erythema, edema, external dysuria
Match the test to species and complexity
Recurrence, severity, host, and organism change care
A positive test without symptoms is not an indication
Recognize the clinical syndrome
Pruritus, vulvar soreness, external dysuria, dyspareunia, erythema, edema, fissures, and thick discharge can occur, but none is specific. Vaginal pH is usually below 4.5.
Require evidence in context
Budding yeast, hyphae, or pseudohyphae on KOH preparation supports VVC. When microscopy is negative but symptoms persist, culture can identify a broader range of yeasts. Asymptomatic colonization is not treated.
Classify uncomplicated disease
Uncomplicated VVC is sporadic or infrequent, mild to moderate, likely caused by C. albicans, and occurs in a nonimmunocompromised patient.
Classify complicated disease
Recurrent, severe, non-albicans, diabetic, immunocompromised, or immunosuppressed phenotypes need additional diagnostic and treatment structure. Recurrent VVC is generally at least three symptomatic episodes in less than one year under CDC guidance.
Find organisms microscopy can miss
C. glabrata may not form hyphae or pseudohyphae and may be missed on routine microscopy. Culture, species identification, and selected susceptibility testing matter when symptoms persist despite therapy.
Quick check
Checking for saved practice…
Lesson
Use Azole and OTC Therapy with Product Precision
Uncomplicated VVC can respond to short-course topical azoles or a single oral fluconazole dose in an appropriate nonpregnant patient. Safe use depends on exact product, route, duration, interactions, reproductive context, and triage.
- Topical azole
- Fluconazole
- OTC triage
- Vehicle
- CYP interaction
- Follow-up
Balance pregnancy, interactions, route, and preference
One, three, seven, and longer courses are not interchangeable
Leakage, irritation, and barrier compatibility matter
Return to diagnosis rather than repeating indefinitely
Choose topical or oral therapy
Topical clotrimazole, miconazole, tioconazole, butoconazole, or terconazole regimens vary from one to 14 days. Oral fluconazole 150 mg once is an option for uncomplicated VVC in selected nonpregnant patients.
Triage OTC requests
Refer first episodes, uncertain diagnosis, pregnancy, severe symptoms, fever, pelvic pain, foul odor, rapid recurrence, frequent episodes, diabetes, immune compromise, suspected STI, or treatment failure for evaluation rather than repeatedly selling empiric products.
Match formulation to duration
CDC lists clotrimazole cream 1% (5 g daily, 7 to 14 days) or 2% (5 g daily, three days); miconazole cream 2% (5 g daily, seven days) or 4% (5 g daily, three days). Miconazole suppositories use 100 mg daily for seven days, 200 mg daily for three days, or 1,200 mg once. Terconazole cream uses 5 g daily: 0.4% for seven days or 0.8% for three days; its 80 mg suppository uses three daily doses. Tioconazole 6.5% ointment and single-dose bioadhesive butoconazole 2% cream each use one 5 g intravaginal application. Verify the actual package and patient eligibility.
Close the self-care loop
Teach the patient to complete the exact labeled course and define what happens next. Persistent symptoms after treatment, worsening symptoms, or recurrence within two months require clinical evaluation and testing rather than another unexamined OTC cycle.
Teach dosage-form technique
Verify cream, ointment, suppository, or ovule strength and duration. Discuss placement, likely leakage, local irritation, full-course completion, and the exact product's effect on condoms or diaphragms.
Apply the miconazole safety details
Vaginal miconazole still carries a warfarin bleeding warning: obtain clinician or pharmacist review before use. The 2% cream label directs medical review if symptoms do not improve within three days or persist beyond seven. During treatment avoid tampons, douches, spermicides and vaginal intercourse; condoms and diaphragms may fail. Patients younger than 12 need clinician guidance. Continue the seven-night course if menstruation begins; use unscented pads rather than tampons. The labeled cream can also be applied to symptomatic external vulvar skin twice daily for up to seven days, but external relief does not replace the intravaginal course.
Do not replace treatment with probiotics
Current CDC guidance finds no substantial evidence for probiotics or homeopathic products as VVC treatment. Persistent symptoms need reassessment, not unproven substitution.
Review systemic exposure
Oral fluconazole can create clinically important CYP interactions and requires reproductive, hepatic, QT, and medication review. Topical exposure is lower but not equivalent to zero, and local products can still cause irritation.
Define treatment failure
Persistent symptoms, return within two months, repeated episodes, or worsening signs require diagnostic reassessment. Do not automatically extend therapy without considering BV, trichomoniasis, dermatitis, vulvodynia, or resistant and non-albicans yeast.
Quick check
Checking for saved practice…
Lesson
Build a Recurrent and Non-Albicans Candidiasis Plan
Recurrent, severe, and non-albicans VVC need organism confirmation, adequate induction, a defined maintenance or alternative regimen, interaction and reproductive safeguards, and a reassessment plan.
- Recurrent VVC
- Induction
- Maintenance
- Non-albicans Candida
- Boric acid
- Susceptibility
Confirm the organism and complicated phenotype
Control active disease before maintenance
Monitor interactions, organ function, and reproduction
Use species-aware therapy and specialist support
Confirm recurrent disease
Document symptomatic episodes and obtain culture or validated testing. Review diabetes, antibiotics, immunosuppression, pregnancy, medication interactions, and whether the apparent recurrences were ever organism confirmed.
Induce remission before maintenance
For recurrent C. albicans VVC, CDC describes seven to 14 days of topical therapy or fluconazole 100, 150, or 200 mg orally on days 1, 4, and 7 before weekly maintenance when oral therapy is appropriate.
Use time-limited maintenance
Fluconazole 100, 150, or 200 mg weekly for six months is a CDC maintenance approach. It controls recurrence but is rarely curative long term, so liver, interaction, reproductive, adherence, and relapse plans remain necessary.
Treat severe disease adequately
Severe erythema, edema, excoriation, or fissuring requires seven to 14 days of topical azole or fluconazole 150 mg orally followed by another 150 mg dose 72 hours later when oral therapy is appropriate.
Handle non-albicans disease cautiously
Exclude other causes, confirm species, and use a longer nonfluconazole azole course when appropriate. CDC describes intravaginal boric acid 600 mg daily for three weeks after recurrence, but it must never be swallowed. Pregnancy requires the separate seven-day topical azole pathway; do not substitute boric acid. Keep capsules inaccessible to children and use a clinician-directed plan.
Quick check
Checking for saved practice…
Lesson
Place Newer Antifungals in the Correct Population
Ibrexafungerp and oteseconazole expand recurrent VVC care through distinct mechanisms and regulatory boundaries. Neither replaces diagnostic confirmation or careful reproductive and interaction review.
- Ibrexafungerp
- Glucan synthase
- Oteseconazole
- CYP51
- Reproductive potential
- BCRP
Glucan synthase inhibition outside the azole pathway
Selective fungal CYP51 inhibition
Pregnancy and reproductive potential define eligibility
CYP3A, BCRP, food, kidney, and liver details differ
Use ibrexafungerp by labeled regimen
Ibrexafungerp inhibits glucan synthase through a non-azole triterpenoid scaffold. For adults and post-menarchal pediatric females, the labeled VVC regimen is 300 mg orally, then 300 mg about 12 hours later, on one day only. Each dose is two 150 mg tablets, totaling four tablets or 600 mg. For recurrence reduction, repeat that one-day regimen monthly for six months. Take with or without food.
Protect against embryo-fetal exposure
Ibrexafungerp carries a boxed warning and is contraindicated in pregnancy. Verify pregnancy before treatment, reassess before each monthly recurrent-disease dose, and use effective contraception throughout the entire six-month recurrence-reduction course, including the intervals between monthly doses, and for four days after the final dose. For acute treatment, contraception continues through treatment and four days afterward.
Review ibrexafungerp interactions
Avoid strong or moderate CYP3A inducers. With a strong CYP3A inhibitor, reduce each of the two doses to 150 mg about 12 hours apart for one day, totaling 300 mg. Weak or moderate CYP3A inhibitors do not require this reduction. GI adverse effects and access can influence whether the regimen is practical.
Separate ibrexafungerp evidence gaps
No dose adjustment is recommended for mild or moderate hepatic impairment; severe hepatic impairment has not been studied. Human milk and breastfed-infant data are absent, so lactation needs an individualized benefit-risk discussion rather than applying oteseconazole contraindications to this different drug.
Use oteseconazole only in the labeled population
Oteseconazole inhibits fungal CYP51 and is indicated only to reduce recurrent VVC incidence in females with a history of recurrence who are not of reproductive potential. Contraception alone does not satisfy this restriction.
Distinguish the two oteseconazole schedules
Oteseconazole-only: 600 mg on day 1, 450 mg on day 2, then 150 mg weekly for 11 doses starting day 14. The alternative starts with fluconazole 150 mg on days 1, 4 and 7; oteseconazole follows at 150 mg daily on days 14 through 20, then 150 mg weekly for 11 doses starting day 28. Do not merge the schedules. Swallow capsules whole with food.
Explain eligibility and transporter risk
Postmenopause or permanent infertility can establish absence of reproductive potential; temporary contraception cannot. Oteseconazole inhibits BCRP and can raise rosuvastatin exposure. Review the substrate dose and monitor adverse effects with the prescriber.
Follow the full oteseconazole product plan
Choose one labeled induction and maintenance regimen, administer with food, review BCRP substrates, and avoid use in pregnancy, lactation, reproductive potential, severe renal impairment, end-stage kidney disease, or moderate to severe hepatic impairment.
Quick check
Checking for saved practice…
Lesson
Close the Plan Across Pregnancy, Lactation, Partners, and Follow-Up
The final therapeutic choice is shaped by pregnancy, lactation, age, immune status, partner needs, product access, stigma, health literacy, and a defined measure of success.
- Pregnancy
- Lactation
- Partner management
- Communication
- Retesting
- Escalation
Use drug, dose, timing, and indication evidence
Plan interruptions and restart timing when required
Trichomoniasis, BV, and VVC are not managed alike
Define improvement, retesting, recurrence, and red flags
Use pregnancy-specific candidiasis care
CDC recommends only topical azole therapy for seven days during pregnancy. Do not use retired pregnancy letter categories, and do not treat routine oral fluconazole as an equivalent pregnancy option.
Treat symptomatic BV and trichomoniasis in pregnancy
Symptomatic pregnant patients with BV should be treated. CDC recommends testing and treatment for symptomatic trichomoniasis at any pregnancy stage. Some current oral metronidazole labels still list first-trimester trichomoniasis as contraindicated; document this guideline-label difference and coordinate prescribing with obstetric care rather than leaving symptomatic infection untreated. Avoid tinidazole during pregnancy. CDC also advises avoiding secnidazole for pregnancy-associated BV because evidence is insufficient. Coordinate obstetric assessment when pain, bleeding, fever, membrane concerns, or other complications are present.
Individualize lactation
Use the exact product label and current lactation evidence. Secnidazole labeling advises stopping breastfeeding for 96 hours after the dose, which requires a practical feeding and restart plan rather than a vague warning.
Keep partner rules distinct
Treat partners for trichomoniasis. Routine partner treatment is not supported for candidiasis. For selected recurrent symptomatic BV, use the newer ACOG shared-decision pathway rather than applying a universal rule.
Measure the outcome
Define expected improvement, adverse effects, treatment completion, retesting when indicated, recurrence threshold, and urgent warning signs. Use neutral language and teach-back so the plan can actually be carried out.
Quick check
Checking for saved practice…
Module practice
Check the connections.
Each attempt draws 10 questions from the complete 37 question bank.
Each attempt draws a fresh set and rearranges the answer choices.
References
Current clinical foundation.
Core source material was synthesized with the following contemporary guidance. Verify local policy and current guidance before applying clinical information.
- DailyMed. Oral metronidazole label
- NYSDOH 2026. Partner treatment to prevent recurrent BV
- DailyMed. Miconazole 7 vaginal cream Drug Facts
- CDC. Diseases characterized by vulvovaginal symptoms
- CDC. Bacterial vaginosis
- CDC. Trichomoniasis
- CDC. Vulvovaginal candidiasis
- ACOG. Concurrent partner treatment for recurrent bacterial vaginosis
- New England Journal of Medicine. Male-partner treatment to prevent BV recurrence
- DailyMed. Secnidazole oral granules
- DailyMed. Ibrexafungerp
- DailyMed. Oteseconazole
- DailyMed. Xaciato clindamycin vaginal gel